{"id":3262,"date":"2025-04-22T23:02:49","date_gmt":"2025-04-22T23:02:49","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/04\/22\/bristol-cobenfy-antipsychotic-disappoints-as-supplemental\/"},"modified":"2025-04-22T23:02:49","modified_gmt":"2025-04-22T23:02:49","slug":"bristol-cobenfy-antipsychotic-disappoints-as-supplemental","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/04\/22\/bristol-cobenfy-antipsychotic-disappoints-as-supplemental\/","title":{"rendered":"STAT+: Bristol\u2019s Cobenfy disappoints as supplemental antipsychotic drug"},"content":{"rendered":"

STAT+: Bristol\u2019s Cobenfy disappoints as supplemental antipsychotic drug
\n \t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

A landmark new treatment for schizophrenia didn\u2019t provide additional benefits to patients when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday.<\/p>\n

The drug, Cobenfy, was approved<\/a> last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades. Doctors and patients hope it can\u00a0 provide an alternative to generic antipsychotics, which can often curb key symptoms but come with significant side effects.<\/p>\n

In the new trial, Bristol tested to see whether Cobenfy could also work in combination with a generic antipsychotic to provide more relief than one drug alone. The answer, at least in this study, was no.<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Jason Mast
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: Bristol\u2019s Cobenfy disappoints as supplemental antipsychotic drug A landmark new treatment for schizophrenia didn\u2019t provide additional benefits to patients when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday. The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2432,2152],"tags":[2150],"class_list":["post-3262","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-mental-health","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3262"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=3262"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3262\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=3262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=3262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=3262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}